MA29107B1 - Conjugues du facteur de croissance 1 analogue a l'insuline et du poly(ethylene glycol) - Google Patents
Conjugues du facteur de croissance 1 analogue a l'insuline et du poly(ethylene glycol)Info
- Publication number
- MA29107B1 MA29107B1 MA30023A MA30023A MA29107B1 MA 29107 B1 MA29107 B1 MA 29107B1 MA 30023 A MA30023 A MA 30023A MA 30023 A MA30023 A MA 30023A MA 29107 B1 MA29107 B1 MA 29107B1
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- insulin
- poly
- ethylene glycol
- growth factor
- Prior art date
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030415A EP1674113A1 (fr) | 2004-12-22 | 2004-12-22 | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29107B1 true MA29107B1 (fr) | 2007-12-03 |
Family
ID=34927913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30023A MA29107B1 (fr) | 2004-12-22 | 2007-06-21 | Conjugues du facteur de croissance 1 analogue a l'insuline et du poly(ethylene glycol) |
Country Status (21)
Country | Link |
---|---|
US (5) | US20060154865A1 (fr) |
EP (2) | EP1674113A1 (fr) |
JP (1) | JP4954896B2 (fr) |
KR (3) | KR20090010138A (fr) |
CN (1) | CN101123991B (fr) |
AR (1) | AR052842A1 (fr) |
AU (1) | AU2005318387B2 (fr) |
BR (1) | BRPI0515857A (fr) |
CA (1) | CA2592006C (fr) |
CR (1) | CR9177A (fr) |
EA (1) | EA011284B1 (fr) |
IL (1) | IL183966A (fr) |
MA (1) | MA29107B1 (fr) |
MX (1) | MX2007007479A (fr) |
NO (1) | NO20073103L (fr) |
NZ (1) | NZ555840A (fr) |
TN (1) | TNSN07237A1 (fr) |
TW (3) | TW200940085A (fr) |
UA (1) | UA93666C2 (fr) |
WO (1) | WO2006066891A2 (fr) |
ZA (1) | ZA200705146B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674113A1 (fr) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
AU2007255419A1 (en) | 2006-06-09 | 2007-12-13 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
CL2007002502A1 (es) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
BRPI0715754A2 (pt) | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
EP2274016B1 (fr) * | 2008-04-03 | 2012-07-25 | F. Hoffmann-La Roche AG | Variantes de l'igf-i pegylées pour utilisation dans le traitement des troubles neuromusculaires |
JP2012513477A (ja) * | 2008-12-23 | 2012-06-14 | ソーク インスティチュート フォー バイオロジカル スタディーズ | 神経変性疾患の治療方法 |
EP2456788B1 (fr) | 2009-07-22 | 2015-12-16 | Ipsen Pharma S.A.S. | Analogues au facteur-1 de croissance insulinomimétique (igf-1) présentant une substitution d'acide aminé en position 59 |
WO2011041376A1 (fr) * | 2009-09-30 | 2011-04-07 | Prolong Pharmaceuticals | Facteur modifié de stimulation des colonies de granulocytes (g-csf) |
US20110152188A1 (en) | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
US9587006B2 (en) * | 2010-02-11 | 2017-03-07 | Hoffmann-La Roche Inc. | IGF-I poly (ethylene glycol) conjugates |
CN101831067A (zh) * | 2010-05-31 | 2010-09-15 | 王二新 | 聚乙二醇脂类缀合物及其在制备药物中的应用 |
EP2864353B1 (fr) * | 2012-06-25 | 2019-03-27 | The Brigham and Women's Hospital, Inc. | Thérapie sélective des cartilages |
NZ708091A (en) | 2012-12-18 | 2018-03-23 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
JP2016535080A (ja) | 2013-10-02 | 2016-11-10 | ノバルティス アーゲー | 療法における使用のためのインスリン様成長因子模倣物 |
UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
EP3702470A3 (fr) * | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer |
KR200481741Y1 (ko) | 2016-02-22 | 2016-11-04 | 강진범 | 차량의 방향지시등에 연동하여 특수 인식 영역에 led 반사광을 형성하기 위한 노면 광조사 장치 |
JP7118508B2 (ja) | 2016-02-23 | 2022-08-16 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト | 神経損傷を治療するペプチドベースの方法 |
RU2711111C1 (ru) * | 2018-09-05 | 2020-01-15 | Илья Владимирович Духовлинов | Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения |
EP3911668A1 (fr) | 2019-01-18 | 2021-11-24 | The Regents of the University of Colorado, a body corporate | Peptides antimicrobiens alpha-hélicoïdaux amphipathiques pour le traitement d'infections par des agents pathogènes à gram-négatif |
US20220299524A1 (en) * | 2021-03-19 | 2022-09-22 | Quest Diagnostics Investments Llc | Identification and quantitation of insulin-like growth factor-i variants by mass spectrometry |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0561137B1 (fr) | 1983-04-25 | 2002-07-03 | Chiron Corporation | Synthèse à l'aide d'ADN hybride de facteurs de croissance mûrs du type insuline |
IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5164370A (en) * | 1987-12-24 | 1992-11-17 | Gropep Pty. Ltd. | Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) |
DE69026306T2 (de) | 1989-05-27 | 1996-10-17 | Seikagaku Kogyo Co Ltd | Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine. |
DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
ES2101865T3 (es) | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
AU6048294A (en) * | 1992-11-25 | 1994-06-22 | Amgen Boulder Inc. | Modified insulin-like growth factors |
EP0756494A1 (fr) * | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Facteurs de croissance proches de l'insuline modifies |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
WO1998035026A1 (fr) | 1997-02-06 | 1998-08-13 | Novo Nordisk A/S | Conjugats polypeptide-polymere a groupes de fixation ajoutes et/ou retires |
US7067485B2 (en) | 1997-11-07 | 2006-06-27 | Chiron Corporation | IGF-I composition and its use |
US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
WO1999055362A1 (fr) | 1998-04-29 | 1999-11-04 | Genentech, Inc. | Formulations de igf-i sechees par pulverisation |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
EP1141015B1 (fr) | 1999-01-06 | 2009-07-15 | Genentech, Inc. | Variants mutants du facteur de croissance i semblable a l'insuline (igf) |
DK1141014T3 (da) * | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
ES2208305T3 (es) | 1999-04-08 | 2004-06-16 | Genentech, Inc. | Composicion basada en polipeptidos de carga opuesta.. |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
HUP0302674A2 (hu) * | 1999-08-27 | 2003-11-28 | Maxigen Aps. | Új, béta-interferon-szerű molekulák |
US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
WO2001091798A2 (fr) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
WO2002032449A2 (fr) | 2000-10-13 | 2002-04-25 | Chiron Corporation | Procede de traitement d'accidents ischemiques affectant le systeme nerveux central |
BR0317752A (pt) * | 2002-12-26 | 2005-11-22 | Mountain View Pharmaceuticals | Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada |
EP1674113A1 (fr) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
EP2274016B1 (fr) | 2008-04-03 | 2012-07-25 | F. Hoffmann-La Roche AG | Variantes de l'igf-i pegylées pour utilisation dans le traitement des troubles neuromusculaires |
-
2004
- 2004-12-22 EP EP04030415A patent/EP1674113A1/fr not_active Withdrawn
-
2005
- 2005-12-20 US US11/313,101 patent/US20060154865A1/en not_active Abandoned
- 2005-12-21 WO PCT/EP2005/013756 patent/WO2006066891A2/fr active Application Filing
- 2005-12-21 TW TW098120879A patent/TW200940085A/zh unknown
- 2005-12-21 CN CN2005800485069A patent/CN101123991B/zh not_active Expired - Fee Related
- 2005-12-21 NZ NZ555840A patent/NZ555840A/en not_active IP Right Cessation
- 2005-12-21 UA UAA200708134A patent/UA93666C2/ru unknown
- 2005-12-21 KR KR1020097000308A patent/KR20090010138A/ko not_active Application Discontinuation
- 2005-12-21 TW TW097145363A patent/TW200914041A/zh unknown
- 2005-12-21 AU AU2005318387A patent/AU2005318387B2/en not_active Ceased
- 2005-12-21 EA EA200701234A patent/EA011284B1/ru not_active IP Right Cessation
- 2005-12-21 CA CA2592006A patent/CA2592006C/fr not_active Expired - Fee Related
- 2005-12-21 BR BRPI0515857-5A patent/BRPI0515857A/pt not_active Application Discontinuation
- 2005-12-21 EP EP05849990.6A patent/EP1830889B1/fr active Active
- 2005-12-21 JP JP2007547330A patent/JP4954896B2/ja not_active Expired - Fee Related
- 2005-12-21 KR KR1020097014300A patent/KR101106860B1/ko not_active IP Right Cessation
- 2005-12-21 TW TW094145672A patent/TW200635604A/zh unknown
- 2005-12-21 KR KR1020077016867A patent/KR100915278B1/ko not_active IP Right Cessation
- 2005-12-21 MX MX2007007479A patent/MX2007007479A/es active IP Right Grant
- 2005-12-22 AR ARP050105473A patent/AR052842A1/es not_active Application Discontinuation
-
2007
- 2007-06-12 CR CR9177A patent/CR9177A/es not_active Application Discontinuation
- 2007-06-14 IL IL183966A patent/IL183966A/en not_active IP Right Cessation
- 2007-06-18 NO NO20073103A patent/NO20073103L/no not_active Application Discontinuation
- 2007-06-21 MA MA30023A patent/MA29107B1/fr unknown
- 2007-06-21 TN TNP2007000237A patent/TNSN07237A1/fr unknown
- 2007-06-21 ZA ZA200705146A patent/ZA200705146B/en unknown
-
2010
- 2010-06-02 US US12/791,904 patent/US20110009317A1/en not_active Abandoned
-
2012
- 2012-07-18 US US13/551,648 patent/US20120322732A1/en not_active Abandoned
-
2013
- 2013-03-18 US US13/845,179 patent/US20130217623A1/en not_active Abandoned
-
2014
- 2014-09-10 US US14/482,703 patent/US9724425B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29107B1 (fr) | Conjugues du facteur de croissance 1 analogue a l'insuline et du poly(ethylene glycol) | |
FR22C1043I1 (fr) | Conjugues de groupe fonctionnel a facteur polymerique viii | |
DE602004021005D1 (de) | Erweiterte aufwärtsstreckenbetrieb bei soft-weiterreichung | |
ATE390099T1 (de) | Zwischenwirbelkunststoffimplantat | |
DE60115227D1 (de) | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga | |
EP1642459A4 (fr) | Sequence video continue a double codage partiel utilisant des tables d'index de programmes | |
DK1542716T3 (da) | Væksthormonfrigivende peptider | |
IL163006A (en) | Polyalkylene glycol polymers and conjugates thereof with biologically active compounds | |
DK1344773T3 (da) | Væksthormonsekretionsfremmere | |
EP1620120A4 (fr) | Conjugues actifs sur le plan biologique a action prolongee | |
DE60309546D1 (de) | Maximal-a-posteriori-Wahrscheinlichtkeitsdetektor | |
EE200300269A (et) | Fibroblasti kasvufaktorid | |
MA26998A1 (fr) | Conjugues peg de hgt-nk4 | |
SE0302124L (sv) | Hatthylla för en cabriolet | |
GB2411404B (en) | Biologically active peptide conjugates | |
DE50112471D1 (de) | Erntegutförderanordnung | |
IL173194A0 (en) | Human growth hormone in parkinson-plus syndromes | |
ITRE20030042A0 (it) | "antenna planetare multibanda" | |
ATE445634T1 (de) | Antimikrobielle peptide | |
ATE419271T1 (de) | Antimikrobielle peptide | |
FI20011396A (fi) | Pölynimurin suulake | |
FI20012010A0 (fi) | Avoauto | |
ITMI20001295A0 (it) | Tavolo da tennis tavolo pieghievole | |
NO20031468D0 (no) | Integrert lys i telt | |
DE10292657D2 (de) | Absaugvorrichtung für einen Tunnel |